Cost-effectiveness of pembrolizumab plus chemotherapy as first line treatment in PD-L1-positive metastatic TNBC. Supplementary Tables.
收藏数据链接：
官方服务：
资源简介：
<strong>Supplementary Table S1. </strong>AIC/BIC of parametric function fitting for OS, PFS and ToT <br> <strong>Supplementary Table S2.</strong> AE related hospitalization costs (2021 USD) <br> <strong>Supplementary Table S3.</strong> Summary of scenario analyses results <br> <strong>Supplementary Table S4.</strong> Summary of subgroup analysis results <br> <strong>Supplementary Table S5.</strong> Cost-effectiveness results for pembrolizumab plus chemotherapy (weighted average) vs. chemotherapy (weighted average)
提供机构：
Taylor & Francis创建时间：
2022-07-07
